上海交通大学学报（医学版）

›› 2012, Vol. 32 ›› Issue (2): 226-.doi: 10.3969/j.issn.1674-8115.2012.02.022

• 综述 • 上一篇    下一篇

糖尿病黄斑水肿抗血管内皮生长因子治疗进展

索 燕, 刘 堃, 许 迅   

  1. 上海交通大学附属第一人民医院眼科, 上海 200080
  • 出版日期:2012-02-28 发布日期:2012-02-28
  • 通讯作者: 许 迅, 电子信箱: drxuxun@sjtu.edu.cn。
  • 作者简介:索 燕（1986—）, 女, 硕士生；电子信箱: jeanette_suoyan@126.com。
  • 基金资助:

    上海市眼底病重点实验室开放课题基金（07Z22911）

Update on anti-vascular endothelial growth factor treatment for diabetic macular edema

SUO Yan, LIU Kun, XU Xun   

  1. Department of Ophthalmology, the First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China
  • Online:2012-02-28 Published:2012-02-28
  • Supported by:

    Shanghai Key Laboratory for Ocular Fundus Diseases Foundation, 07Z22911

PDF (PC)

1494

摘要：

糖尿病黄斑水肿（DME）是导致糖尿病患者视功能损伤的主要原因之一，DME的治疗方法包括激光光凝治疗、抗炎治疗和抗血管内皮生长因子（VEGF）治疗。近年来，抗VEGF药物Ranibizumab、Bevacizumab、VEGF-Trap和KH902等对DME有良好的治疗效果。文章对DME抗VEGF治疗进展进行综述，探讨抗VEGF治疗的有效性和安全性。

关键词: 糖尿病黄斑水肿, 激光光凝, 抗炎治疗, 抗血管内皮生长因子药物

Abstract:

Diabetic macular edema (DME) is one of the major causes of visual impairment in patients with diabetes mellitus. The major treatment methods for DME include laser photocoagulation therapy, anti-inflammatory therapy and anti-vascular endothelial growth factor (VEGF) therapy. In recent years, anti-VEGF drugs such as Ranibizumab, Bevacizumab, VEGF-Trap and KH902 have exhibited favorable effects in treatment of DME. The research progress of anti-VEGF therapy for DME is reviewed in this paper, and the efficacy and safety of anti-VEGF therapy are explored.

Key words: diabetic macular edema, laser photocoagulation, anti-inflammatory therapy, anti-vascular endothelial growth factor drug